Malignant Metastatic Insulinoma Treated With Streptozotocin

Gefel, A; Flatau, E; Ayalon, Daniel; Papo, J; Loewenthal, M

doi:10.1111/j.1365-2265.1975.tb01555.x

Cited by 10 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic chemotherapy is indicated in patients with inoperable metastatic insulinomas. Streptozotocin and doxorubicin are generally used in these cases [16, 17, 18]. …”

Section: Therapymentioning

confidence: 99%

Insulinoma

Herder¹

2004

Neuroendocrinology

View full text Add to dashboard Cite

More than 90% of insulinomas are benign tumors. Insulinomas cause hypoglycemia and thereby symptoms of neuroglycopenia and catecholamine response. During symptoms, blood glucose levels should be less than 40 mg/dl (less than 2.2 mmol/l), concomitant insulin levels should be ≧6 IU/ml (≧43 pmol/l) and concomitant C-peptide levels ≧0.2 pmol/l. Most insulinomas can be identified intraoperatively by experienced surgeons. Initial therapy consists of administration of frequent meals and/or by glucose infusion. In patients with solitary insulinomas, complete surgical removal of the tumor should be the primary goal. In patients with metastatic insulinomas, symptoms of insulin hypersecretion will only completely disappear after complete resection of all metastases.

show abstract

“…Systemic chemotherapy is indicated in patients with inoperable metastatic insulinomas. Streptozotocin and doxorubicin are generally used in these cases [16, 17, 18]. …”

Section: Therapymentioning

confidence: 99%

Insulinoma

Herder¹

2004

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…Insulinoma was one of the first panNETs treated with STZ [35-42]. By way of a historical report, we will comment on the case reported by Arnould et al [36] in 1969 in The Lancet .…”

Section: Treatment Of Patients With Pannets With Stzmentioning

confidence: 99%

Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors

et al. 2022

View full text Add to dashboard Cite

On May 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year marks forty years since that landmark date. This review of streptozotocin to treat panNETs is intended to commemorate this anniversary. A historical perspective of chemical structure, pharmacokinetics, and mechanism of action of streptozotocin is followed by data from prospective and retrospective clinical studies. The last section of the review addresses the latest aspects and takes note of the prospects that lie ahead on the future horizon of the use of streptozotocin to treat panNETs, including ongoing clinical trials.

show abstract

“…Most patients were 50-65 years old (mean 56). In addition to the more common symptoms and signs, the following features were noted: high serum gash-in and glucagon values (10, 1 l), pathological liver enzyme activities (2,7,16), gastric or duodenal peptic ulcer (5, 10, 13), watery diarrhoea (7, ll), multiple endocrine adenomatosis in a 6-year-old child. This patient developed an active insulinoma with a tumour, severe obesity and vinlization (17).…”

Section: Case Reportmentioning

confidence: 99%

Treatment of Malignant Metastatic Pancreatic Insulinoma with Streptozotocin

Herbai

Lundin

1976

Journal of Internal Medicine

View full text Add to dashboard Cite

ABSTRACT. The possibilities of treating different types of pancreatic islet cell cancer with the active drug streptozotocin have been studied in reports of 21 patients published during the last 8 years. The unusual features of the symptomatology, dosage and injection methods, side‐effects after different infusion schedules and complications of streptozotocin therapy, are compared. A new case with pancreatic carcinoma and liver metastases was treated with a total dose of 14 g streptozotocin, divided into 7 injections with an increasing interval between them. This patient underwent a marked amelioration of the disease, without serious side‐effects of the streptozotocin treatment. She has been apparently well for the 22 months which have now elapsed since the beginning of treatment. This seems to be one of the longest remission periods yet published in the insulinoma literature.

show abstract

Malignant Metastatic Insulinoma Treated With Streptozotocin

Cited by 10 publications

References 18 publications

Insulinoma

Insulinoma

Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors

Treatment of Malignant Metastatic Pancreatic Insulinoma with Streptozotocin

Contact Info

Product

Resources

About